Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Bellicum Pharma inks Global License Agreement with Agensys to develop and commercialize adoptive cell therapies, including CAR-T cells, for tumors expressing Prostate Stem Cell Antigen (PSCA)

Source Link:: http://seekingalpha.com/news/2979156-bellicum-inks-license-deal-psca-targeted-cell-therapies-agensys

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

BLCM

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Management Comment "PSCA is an attractive target for our CAR-T cell technology and the license agreement allows Bellicum to advance BPX-601 into a number of cancers where there is a significant unmet medical need. We look forward to the expected advancement of BPX-601 into clinical development in the first half of 2016 for the initial target indication of pancreatic cancer."

-CEO Thomas Farrell

http://seekingalpha....

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Dec 11, 2015

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Licensing Agreement, Commercialization, Adoptive Cell Therapies, Car-t, Prostate Cancer, Bladder Cancer, Gastric Cancer, Pancreatic Cancer